Table 2.
Literature review of MDM2 and CDK4 in head & neck osteosarcoma
| Article | Craniofacial osteosarcomas | Benign lesions | |||||
|---|---|---|---|---|---|---|---|
| MDM2 IHC | CDK4 IHC | MDM2 amp | CDK4 amp | Grade evaluated | Subtype evaluated | MDM2 & CDK4 IHC | |
| Lopes et al. [6] | 8/9 (89%) 4 strong | 5/9 (56%) all strong | 6/9 (67%) | 6/9 (67%) | All | Chondroblastic osteoblastic parosteal | NP |
| Junior et al. [5] | 6/25 (24%) 2 moderate 4 weak | 21/25 (84%) 10 strong 9 moderate 2 weak | NP | NP | Intermediate high | Chondroblastic osteoblastic | NP |
| Yoshida et al. [10] | 3/3 (100%) 1 strong diffuse 1 moderate diffuse 1 moderate focal | 1/3 (33%) strong diffuse | NP | NP | Low | Fibroblastic | 1/40 EC (3%) ulnar BPOP pos |
| Guerin et al. [8] | 3/36 (8%) UNK pattern | NP | 5/14 (36%) | NP | High | Chondroblastic osteoblastic fibroblastic | 0/25 CF (0%) MDM2 only UNK histology |
| Hirose et al. [13] | 1/1 | 1/1 | 1/1 | 1/1 | High | Osteoblastic, giant cell rich | NP |
| Dujardin et al. [9] | NP | NP | NP | NP | NP | NP | 0/97 EC (0%) 0/10 CF (0%) 6 COF, 2 FD, 1 OD, 1 MF |
| Lott Limbach (current) | 7/11 (63%) all focal weak | 7/11 (63%) all focal weak | 1/4 (25%) | NP | All | Chondroblastic osteoblastic fibroblastic |
0/14 CF (0%) 6 FD, 3 COF, 2 POF, 2 CGCL, 1 EO, 1 OFM |
| Total | 28/85 (33%) | 35/49 (71%) | 13/28 (46%) | 7/10 (70%) | All | All | 1/186 (< 1%) |
IHC immunohistochemistry, amp amplification, NP not performed, UNK unknown, EC extracranial, BPOP bizarre parosteal osteochondromatous proliferation, CF craniofacial, COF cemento-ossifying fibroma, FD fibrous dysplasia, OD osseous dysplasia, MF myofibroma, POF peripheral ossifying fibroma, CGCL central giant cell lesion, EO endosteal osteoma, OFM odontogenic fibromyxoma